Pier Capital’s Stemline Therapeutics, Inc. STML Stock Holding History

Pier Capital’s Portfolio STML Stock Details STML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-639,582	Closed	-$8.22M	–	123
2019 Q1	$8.22M	Buy	639,582 +215,915	+51%	+$2.44M	1.28%	19
2018 Q4	$4.03M	Buy	423,667 +171,972	+68%	+$2.23M	0.8%	71
2018 Q3	$4.18M	Buy	+251,695	New	+$4.04M	0.53%	96

Other funds holding STML

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Pier Capital's STML Position: Q2 2019 in Review

Pier Capital sold out of Stemline Therapeutics, Inc. (STML) in Q2 2019, closing a stake of 639,582 shares — an estimated $8.22M sold.

Pier Capital first reported a position in STML in Q3 2018 and held it in 3 quarters. The position peaked at $8.22M in Q1 2019. 96 funds tracked by Wall St. Rank hold STML as of Q2 2019.

Pier Capital reported no remaining Stemline Therapeutics, Inc. position as of Q2 2019 after selling out during the quarter.
Pier Capital sold 639,582 Stemline Therapeutics, Inc. shares in Q2 2019, an estimated $8.22M.
Pier Capital first reported a position in Stemline Therapeutics, Inc. in Q3 2018 and held it in 3 quarters.
Pier Capital's Stemline Therapeutics, Inc. position peaked at $8.22M in Q1 2019.
96 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2019.

Based on Pier Capital's 13F filing for Q2 2019, filed 14 Aug 2019.